Drug intelligence / Profile preview

IN-005

Development stage: Preclinical
Lead developer: Inhalon Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Inhalation, Intranasal

Overview

IN-005 is a monoclonal antibody being developed by Inhalon Biopharma for the treatment of influenza. The drug utilizes a "muco-trapping" antibody platform, which is designed to enhance the retention and activity of antibodies in the respiratory tract by trapping viruses in mucus, thereby preventing their spread and facilitating their clearance from the body. This approach aims to provide effective antiviral therapy directly at the site of infection[1].

Targets

MUC5AC (Mucin-5AC)

Beyond the preview

Go deeper on IN-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN-005.

Explore the full profile